Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

With Editas' third CEO in as many years, expect a new CMO and new development partners

4 years ago

'Empathy and love were not shown’: The story behind Taysha’s layoffs, one of dozens of biotechs suffering this year’s bear market

4 years ago

ARCH leads $130M infusion into Be Bio's long pursuit of B cell therapies for rare disease, cancer

4 years ago

'Truly different': Roche's former hematology leader shifts a new Versant biotech into gear

4 years ago

AACR22: As post-Covid development takes shape, BioNTech reports first human data for CAR-T/cancer vaccine combo

4 years ago

AACR22: Affimed's NK cell therapy produces more patient responses — and more durability questions

4 years ago

Delayed at the EMA, a gene therapy player is grappling with a cash crunch

4 years ago

As part of broader gene therapy ambitions, Takeda links up again with a small Chicago biotech

4 years ago

Doug Melton to reunite with his Semma collaborators at Vertex to develop 'curative cell therapies'

4 years ago

Bluebird joins the layoff flock to reality as gene therapy biotech sheds staff to save itself

4 years ago

Gilead's landmark CAR-T approval leaves Bristol Myers Squibb scrambling for second place

4 years ago

After steering made-in-China CAR-T all the way from obscurity to approval, Frank Fan resigns from Legend

4 years ago

Taysha joins layoff wave as Dallas biotech pauses most of its R&D work

4 years ago

A team at Penn says it has slashed CAR-T cell therapy manufacturing timeframe to just 24 hours

4 years ago

Novartis suffers a loss in its fight to block Regenxbio's Zolgensma patent extension

4 years ago

Dermatology biotech Krystal settles lawsuit from former partner as it prepares first FDA pitch

4 years ago

Genome editing products: FDA recommends at least 15 years of follow-up after clinical trials

4 years ago

CSL and Grifols sue US border patrol for blocking Mexican plasma donations

4 years ago

The offer doesn't stop at Covid. Novartis opens up manufacturing ops to make Carisma’s CAR-M cell therapy

4 years ago

Novartis takes a gamble on Voyager's new AAV tech, inks $1.7B gene therapy discovery pact

4 years ago

So, just how much are those CRISPR patents actually worth?

4 years ago

FDA quickly follows a voluntary pause for CAR-T 2.0 with a clinical hold to investigate 2 patient deaths

4 years ago

Broad Institute lands major victory in CRISPR patent fight over UC Berkeley, Nobel winners

4 years ago

Expanded Intellia CRISPR data set up showdown with Pfizer, Ionis and Alnylam in not-so-rare disease

4 years ago

First page Previous page 30 31 323334 35 36 Next page Last page